

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
6 February 2003 (06.02.2003)

PCT

(10) International Publication Number
WO 03/009839 A1(51) International Patent Classification⁷: A61K 31/343,
A61P 9/06, C07D 307/80(74) Agents: BANNERMAN, David, G. et al.; Withers &
Rogers, Goldings House, 2 Hays Lane, London SE1 2HW
(GB).

(21) International Application Number: PCT/EP02/07905

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 15 July 2002 (15.07.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0117778.1 20 July 2001 (20.07.2001) GB
0117780.7 20 July 2001 (20.07.2001) GB(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).(71) Applicant (*for all designated States except US*): KARO
BIO AB [SE/SE]; Novum, S-141 57 Huddinge (SE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): BRANDTS, Bodo
[DE/DE]; Beerenhang 3, 44797 Bochum (DE). CARLS-
SON, Bo [SE/SE]; Bigarravagen 6, S-114 21 Stockholm
(SE). MALM, Johan [SE/SE]; Korsangarvagen 53, S-142
40 Skogas (SE).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: BENZOFURANES AND THEIR USE IN THE TREATMENT OF ATRIAL FIBRILLATION

(57) Abstract: This invention relates to new compounds and their pharmaceutical use, and to the pharmaceutical use of known compounds, which compounds inhibit certain transmembrane potassium currents in the atrium of the heart of a mammal without significantly affecting other ion channels, for the treatment of heart disease particularly atrial fibrillation. The invention also relates to pharmaceutical compositions comprising such compounds.

WO 03/009839 A1

BENZOFURANES AND THEIR USE IN THE TREATMENT OF ATRIAL FIBRILLATION

FIELD OF THE INVENTION

This invention relates to novel compounds that inhibit certain transmembrane potassium currents in the atrium of the heart of a mammal without significantly affecting other ion channels. It also relates to the use of certain known compounds in the preparation of a medicament for the treatment of heart diseases, particularly atrial fibrillation. It further relates to pharmaceutical compositions containing compounds that inhibit certain transmembrane potassium currents in the atrium of the heart of a mammal without significantly affecting other ion channels, for the treatment of heart disease, particularly atrial fibrillation.

BACKGROUND OF THE INVENTION

Cell membranes have a basic lipid bilayer structure that is impermeable to ions. Special proteins (hereafter referred to as ion-channels) have evolved that provide pathways for ions to cross cell membranes and so make the membrane permeable to ions, such as potassium (hereafter K), as sodium (hereafter Na) or calcium (hereafter Ca). Opening and closing of ion-channels make the membrane permeable or impermeable to different ions and thereby they regulate many properties and functions of the cell membrane. Ion-channels enable cells to set up membrane potentials, and allow currents to flow that change these membrane potentials, thereby underlying electrical signaling by the cell membrane. A transmembrane current (hereafter I) is the ion-flow through an open ion-channel. Ion-channels are targets for many antiarrhythmic drugs, which are used to treat abnormal electrical activity in the heart. From a therapeutic perspective, blocking of K-channels prolongs the action potential duration (APD) and lengthens the refractory period, and is a classical antiarrhythmic mechanism generating a Q-T prolongation on the surface ECG (Singh B and Nademanee K, *Am Heart J*, 1985, 109:421-30).

Several different kinds of ion-channels, including Na- Ca- and K- ion channels, are active in the mammalian heart giving rise to different ion-currents (e.g. I_{Na} , I_{Ca} and I_K). Most K-channels are either voltage activated such as the Delayed Rectifier K-channel (resulting in the current I_K), the Transient Outward K-channel (resulting in the current I_{to}) or ligand operated such as the ATP-sensitive K-channel which is opened during metabolic impairment (when intracellular levels of ATP are reduced) which generates the current $I_K(ATP)$. Another ligand-activated K-channel is the Muscarinic K-channel which is activated when acetylcholine binds to the muscarinic receptor M2 (resulting in the current $I_K(ACh)$) or when adenosine binds to the adenosine receptor A1 (resulting in the current $I_K(Ado)$).

Antiarrhythmic drugs are grouped according to their essential inhibitory effects on certain ion-currents; class I drugs predominantly inhibit sodium currents and class III drugs predominantly inhibit potassium currents. However, antiarrhythmic drugs that are used today are not selective in their ion-channel blocking and every drug used today interacts with several currents.

K-channel blocking in the heart may be one of the most efficient antiarrhythmic mechanisms identified so far. The problem is that any drug that prolongs repolarization has an intrinsically associated risk of inducing *torsade de points* arrhythmia in the ventricle. However, since the K-channels responsible for repolarization actually differ between the atrium and the ventricle, it is possible to identify K-channels that will be active against supraventricular arrhythmias but that will not prolong the QT-interval and thus will not be proarrhythmic.

Blocking of the particular ligand-activated K-currents $I_K(Ado)$ and/or $I_K(ACh)$ has been shown to occur with anti-arrhythmic agents. It has also been postulated that this mechanism may be of importance in explaining the efficacy of anti-arrhythmic drugs for the treatment of atrial fibrillation (Mori K, et al. *Circulation* 1995 Jun 1;91(11):2834-43; Ohmoto-Sekine Y, et al. *Br J Pharmacol* 1999 Feb;126(3):751-61; Watanabe Y, et al. *J Pharmacol Exp Ther* 1996 Nov;279(2):617-24). The ligand-gated currents $I_K(Ado)$, $I_K(ACh)$ and $I_K(ATP)$ probably only have minor roles in shaping repolarization under normal conditions but,

when activated by extracellular acetylcholine, by extracellular adenosine or reduction of intracellular ATP concentrations respectively, these currents are increased and thus can substantially shorten the action potential duration (APD) (Belardinelli L, et al. *FASEB J* 1995; 9(5):359-365; Belardinelli L and Isenberg G. *Am J Physiol* 1983; 244(5):H734-H737; Findlay I and Faivre JF. *FEBS Lett* 1991; 279(1):95-97). The therapeutic effect of anti arrhythmic agents is to prolong APD and thereby make the atrial myocardium more refractive to abnormal electrical activity.

It is expected that the ligand-gated channels IK(Ado) and IK(ATP) are more active in atrial tachyarrhythmias (i.e. atrial fibrillation (AF) and atrial flutter) than in normal sinus-rhythm, whereas IK(ACh) activation is dependent on vagal activity (presynaptic release of ACh). Atrial consumption of ATP is increased in atrial tachyarrhythmias leading to increased levels of adenosine (a metabolite of ATP) activating IK(Ado) and leading to reduced intracellular ATP concentration, hence, activating IK(ATP) (Ashcroft SJ and Ashcroft FM. *Cell Signal* 1990; 2(3):197-214).

Atrial fibrillation is today seldom treated with antiarrhythmic agents to normalize the abnormal electric activity. The primary reason for the reluctance to treat AF-patients with drugs that effectively normalize atrial electric activity is that available anti-arrhythmic drugs also block other ion-channels, in addition to the ligand-gated channels IK(Ado), IK(ACh) and IK(ATP), in the heart. Therefore, treatment of AF-patients with currently-available anti-arrhythmic drugs is associated with a substantial risk to induce lethal proarrhythmic effects (as *Torsade-de Points* in the ventricle). It is of importance to consider that the antiarrhythmic agents referenced in Table 1 are not exclusively active on the ligand-gated currents IK(Ado), IK(ACh) and IK(ATP), but also block other transmembrane currents (references in Table 2).

The class III-agent amiodarone has been shown to be effective for treatment of AF (Roy D, et al., *N Engl J Med* 2000 Mar 30;342(13):913-20) and indeed amiodarone does block ligand-gated currents IK(Ado) and IK(ACh) (Watanabe Y, et al. *supra*). However, in spite of the proven efficacy of amiodarone to treat AF, the side effect profile of the drug is complex; there are features such as pulmonary toxicity, ocular and skin changes, and other

forms of organ toxicity that clearly limit its widespread clinical utility (Pollak, T. M. *Am. J. Cardiol.*, 1999, 84, 37R-45R; Wiersinga, W. M. Chapter 10, Amiodarone and the Thyroid, In Handbook of Experimental Pharmacology, Weetman A. P., Grossman, A., Eds.; Springer-Verlag.: Berlin, Heidelberg, 1997, Vol 128). Amiodarone has a complex pharmacokinetic profile and the elimination of the drug is extremely slow (Wiersingha, supra). In spite of its proven efficacy for treatment of AF, amiodarone is not frequently used as a treatment due to all side effects associated with its use. A novel anti-arrhythmic drug which shares the inhibitory effect on the ligand activated currents $IK(Ado)/IK(ACh)$ with amiodarone but displays lower organ toxicity than that drug would provide an improved treatment for AF. Indeed, data from toxicological studies performed with compounds of the present invention or used in the present invention suggest a reduced toxicity as compared to amiodarone. The extreme pharmacokinetic behavior of amiodarone complicates dosing of that drug and thus it would be of great clinical benefit to have a drug which shares the inhibitory effects on the ligand activated currents $IK(Ado)/IK(ACh)/IK(ATP)$ with amiodarone but that displays mainstream pharmacokinetics. Data from blood pharmacokinetics, tissue distribution and mass balance studies on compounds used in the present invention indicates that the clinical use of these compounds will be less complicated than that of amiodarone. An ideal drug for treatment of atrial fibrillation should also selectively inhibit the atrial currents that are increased under the pathological conditions characterizing the disease and lack effects on other currents. This is the case with the compounds of the present invention since the $IK(Ado)/ATP$ current is predominantly active in the fibrillating atrium and the $IK(ACh)$ is the current responsible for the induction of vagal-triggered atrial fibrillation. In comparison with other antiaarrhythmic drugs (see table 2) the compounds of the present invention are essentially free from interactions with other ion-currents and can therefore be regarded as selective inhibitors of the K-currents ($IK(Ado)$, $IK(ACh)$ and $IK(ATP)$) that have an increased activity in supraventricular cardiac arrhythmias (i.e. atrial fibrillation) but without the ability to block the ion-currents that mediate electrical activity in the cardiac ventricles and in the normal atrium.

Both the compounds that are the subject of the present invention and amiodarone have been shown to antagonize triiodothyronine (T3)-signalling action in cells (manuscript in

preparation) and therefore it should be noted that the inhibitory effects seen with such compounds on IK(Ado), IK(ACh) and IK(ATP)) are not due to T3-antagonism. There are two findings that support this statement; a) T3 does not have acute effects on IK(Ado) or IK(ACh) and b) potent T3-antagonists (100x more potent than the compounds that are the subject of the present invention on T3-receptor mediated signaling) do not display similar acute effects on IK(Ado) or IK(ACh).

DESCRIPTION OF THE INVENTION

In the present invention acute and chronic effects of various compounds have been investigated by using electrophysiology techniques applied to cardiomyocyte cultures. The inventors have found that certain compounds inhibit transmembrane K-currents that are induced through stimulation by muscarinic receptor agonists such as AcetylCholine (ACh) or A1 adenosine receptor agonists such as Adenosine (Ado) and by reduction of intracellular ATP.

The inhibitory effects occur within seconds after induction of the current with ACh, Ado or dinitrophenole (DNP reduces intracellular ATP). The acute inhibitory effects caused by the compounds of the present invention on these K-currents in cardiac muscle tissue had not previously been discovered. The reasons for this include the fact that these ligand activated K-currents (IK(Ado), IK(ACh) and IK(ATP)) are preferentially active in the atrial cardiomyocytes (Workman AJ et al. *Cardiovasc Res* 1999 Sep;43(4):974-84; Koumi S-I, and Wasserstorm A. *American Journal of Physiology* 266[35], H1812-H1821. 1994), while previous studies have been carried out with tissue from cardiac ventricles. Furthermore, IK(Ado) and IK(ACh) must first be induced via the M2 or A1 receptor (with ACh and Ado respectively) before any inhibition can be observed. Without any agonist at the extracellular site of the membrane these ligand-gated channels probably have only minor roles in shaping repolarization but, when activated by extracellular acetylcholine or adenosine, they can substantially shorten action potential duration in the atrium (Tristani-Firouzi M et al. *Am J Med* 2001 Jan;110(1):50-9).

Similar effects (i.e. inhibition of IK(Ado) or IK(ACh)) have been described for other antiarrhythmic drugs such as: E-4031, and MS-551 (Mori et al. supra), aprinidine (Ohmoto et al. supra) Amiodarone (Watanabe et al. supra) and terikalant (Brandts B. et al. *Pacing Clin Electrophysiol* 2000 Nov;23(11 Pt 2):1812-5); see Table 1.

One aspect of the invention is that compounds that are able to block one or both of the K-currents IK(Ado) and IK(ATP) should be efficient as pharmacological treatments for atrial fibrillation and/or atrial flutter.

It is well known that prolonged atrial fibrillation facilitates the persistence and/or reoccurrence of arrhythmia (Wijffels M. et al. *Circulation* 92, 1954-1968. 1995). The pathophysiological background of this observation is the alteration of ion channel expression in atrial myocytes (electrical remodeling; Yue L. et al. *Circulation Research* 81, 512-525. 1997; Yue L. et al. *Circ Res* 1999; 84(7):776-784). Seeking for strategies to treat atrial fibrillation one has to appreciate the fact that electrical remodeling is not the primary cause of the arrhythmia. Electrical remodeling is a phenomenon that develops in patients and in the healthy heart. Other mechanisms than electrical remodeling are suggested to be responsible for the development of the "disease atrial fibrillation". These mechanisms are discussed to be relevant at the early phase of the arrhythmia (a few minutes to a few hours).

The high frequency activation of the atrial myocardium during atrial fibrillation (more than 5Hz) is suggested to significantly increase atrial oxygen consumption and thereby to significantly increase intracellular and interstitial adenosine concentrations due to intracellular loss of ATP. These mechanisms have been well described for ventricular fibrillation (Weiss JN et al. *J Physiol* 1992; 447:649-673; Schrader J. et al. *Experientia* 1990; 46(11-12):1172-1175; Decking UK et al. *Circ Res* 1997; 81(2):154-164; Deussen A. and Schrader J. *J Mol Cell Cardiol* 1991; 23(4):495-504). Due to methodical difficulties at the atrial level (much less tissue, no option to selectively collect atrial effluat) only indirect observations suggest the occurrence of ischaemia during atrial fibrillation. After episodes of atrial fibrillation Daoud et al. showed a reduction of atrial effective refractory period which was abolished after some tens of seconds during sinus rhythm (Daoud EG et al. *Circ* 1996; 94:1600-1606). Furthermore Rubart et al. showed elevated potassium

concentrations during AF (Rubart M. et al. *J Cardiovasc Electrophysiol* 2000; 11(6):652-664). Both observations fit very well with the hypothesis of atrial fibrillation-induced ischaemia in the atria. The consequence of atrial ischaemia during atrial fibrillation would be the activation of IK(Ado) and IK(ATP). Both currents are known to markedly reduce the atrial effective refractory period. A reduction of this period however is known to be one major determinant for the development of reentry tachycardias like atrial fibrillation. Since inhibition of IK(ATP) and IK(Ado) could reverse the shortening of the atrial effective refractory period such an inhibition is expected to be of significant pharmacological value in the treatment of atrial fibrillation. Moreover, since the ventricular tissue is activated at a "normal" rate during atrial fibrillation IK(Ado) and IK(ATP) are not expected to be active. Hence a drug which selectively inhibits IK(Ado) and IK(ATP) will not influence ventricular electrophysiology and hence will not exert dangerous proarrhythmic effects. Furthermore, as mentioned above, IK(Ado) is much less expressed in ventricular myocytes.

Another aspect of the invention is the fact that compounds that are able to block IK(ACh) should be efficient as pharmacological treatments for a defined subgroup of patients in which the pathophysiology of atrial fibrillation has been well defined: Vagal-induced atrial fibrillation is regarded as an arrhythmia occurring when an increased vagal activity reduces the atrial effective refractory period by activation of IK(ACh). Because adenosine- and acetylcholine-induced inward rectifying potassium current is represented by the activation of the same ion channel population (Bünemann M. et al. *J Physiol (Lond)* 1995; 489(3):701-707; Bünemann M. et al. *EMBO* 1996), an inhibitor of adenosine-activated ion channels will also be an effective inhibitor of IK(ACh). Inhibition of IK(ACh) would be of significant value for the treatment of vagal-induced atrial fibrillation.

There is a unique specificity of the compounds that are the subject of the invention to exclusively block the three currents IK(ACh), IK(Ado), and IK(ATP). Several compounds that display well-known anti-arrhythmic properties have been shown to inhibit at least one of these three currents (see Table 2). However, all these other compounds are known to inhibit other ion-currents as well. Table 2 is a compilation of antiarrhythmic drugs that have been shown to inhibit IK(ACh). Interestingly compounds from different classes of

antiarrhythmic compounds have all been shown to display similar actions on this particular current and the compilation includes "second generation" class III antiarrhythmic compounds, such as D-sotalol and Terikalant, which are potent inhibitors of the rapid component of delayed rectifying K-current (IKr). The compilation also includes the class III agents Amiodarone and Dronedarone that are known to inhibit several transmembrane currents (i.e Ca-currents) in addition to the currents listed in table 2. Also class I antiarrhythmic drugs as Flecainide, Quinidine, Disopyramide and Aprinidine are included. The most prominent mechanism of antiarrhythmic activity of these class I compounds is blockade of inward Na-currents.

Results from voltage clamp experiments with compounds of the invention on other ion-currents than IK(Ado), IK(ACh) and IK(ATP) are included in Table 2. Data from these voltage-clamp experiments demonstrate the absence of any relevant inhibition of the currents IK1, IKs, INa and Ito by compounds of the present invention.

The unique selectivity of the compounds that are the subject of the present invention to solely inhibit IK(ACh), IK(Ado), and IK(ATP) suggests that they will be effective in the treatment of atrial fibrillation and/or atrial flutter to normalize pathological electric activity in the atrium. The absence of inhibition of other ion-currents such as the inward rectifier (IK1), the slow component of the delayed rectifier (IKs), the transient outward K-current (Ito) or the depolarizing Na-current (INa) predict the risks for the compounds of the present invention to induce proarrhythmicity in normal cardiac tissue to be minor. Today clinicians are reluctant to treat AF-patients with effective antiarrhythmic drugs due to the intrinsic risks of proarrhythmic effects in the ventricles associated with the currently-available drugs. The selective action of the compounds of the present invention excludes significant effects on ventricular electrophysiology yielding prevention of proarrhythmias at that level. Moreover, the pharmacodynamic profile of the compounds of the present invention is expected to be of special value for the treatment of every kind of atrial fibrillation (inclusive of vagal-induced atrial fibrillation) without ventricular proarrhythmias.


Another aspect of the invention is that the compounds that it is concerned with are at least as potent as the drug amiodarone as blockers of the currents IK(Ado), IK(ACh) and

IK(ATP) and this aspect together with the available safety documentation on the compounds of the present invention, suggesting an apparently much better safety profile than what is seen with amiodarone, indicates that the compounds of the present invention will be at least as efficacious as amiodarone for treatment of AF but with fewer adverse effects.

DETAILED DESCRIPTION OF THE INVENTION

In accordance with a first aspect of the present invention, novel compounds are provided that inhibit certain transmembrane K-currents that are induced through stimulation by muscarinic receptor agonists such as AcetylCholine (ACh) or A1 adenosine receptor agonists such as Adenosine (Ado) and by reduction of intracellular ATP.

Consequently, in a first aspect of the invention there are provided compounds according to the general formula I:



I

wherein;

R₁ is C₁-C₄ alkyl;

R₂ is NHCOR^a, NHCONHR^a, or hydrogen;

R₃ and R₄ are independently selected from fluorine, chlorine, C₁-C₆ alkyl, and CF₃;

R^a is selected from CF₃, C₁₋₃ alkyl, and -(4-R^b)C₆H₄;

R^b is selected from C₁₋₄ alkoxy, hydroxy, fluoro, and nitro;

R₅ is selected from hydrogen and -CH₂-COOH;

X is selected from CH₂ and C=O; with the proviso that when R₅ is

hydrogen, X is -CH₂-;

and pharmaceutically acceptable salts, esters and isomers thereof.

Preferably R₂ is hydrogen. Also preferably, where R₂ is H or NHCOR^a, R₃ and R₄ are independently C₁-C₄ alkyl, and more preferably R₃ and R₄ are both isopropyl.

In compounds where R₅ is -CH₂-COOH, R₁ is preferably methyl; R₂ is preferably hydrogen; R₃ and R₄ are preferably independently C₁-C₄ alkyl; R₅ is preferably -CH₂-COOH; and X is preferably -CH₂-.

Especially preferred compounds of the invention are:

2-methyl-3-(3,5-diisopropyl-4-hydroxybenzoyl)benzofuran (**E1**);

2-methyl-3-(3,5-diisopropyl-4-carboxymethoxybenzoyl)benzofuran (**E2**);


2-methyl-3-(3,5-diisopropyl-4-hydroxybenzyl)benzofuran (**E3**);

2-methyl-3-(3,5-diisopropyl-4-carboxymethoxybenzyl)benzofuran (**E4**);

and pharmaceutically acceptable salts and esters thereof and isomers thereof.

In accordance with a second aspect of the invention there is provided a pharmaceutical use of a compound that inhibits certain transmembrane potassium current, which are more active in the diseased atrium of a mammalian heart than in a normal atrium, without affecting other ion channels, for the preparation of a medicament for the treatment or prevention of atrial fibrillation and atrial flutter. Preferably the said inhibition derives from inhibition of one or several of the three ligand-sensitive potassium currents IK(Ado), IK(ACh) and IK(ATP). The inhibition caused by the said compound is more preferably not due to a T3 antagonistic effect.

The said compounds are described by the general formula II:



II

wherein;

R^6 is C_1-C_4 alkyl;

R^7 is $NHCO R^{10}$, $NHCONHR^{10}$, or hydrogen;

R^8 and R^9 are independently selected from iodine, and bromine;

R^{10} is selected from CF_3 , C_1-C_3 alkyl, and $(4-R^{11})C_6H_4$;

R^{11} is selected from C_1-C_4 alkoxy, hydroxy, fluoro, and nitro;

R^{12} is selected from hydrogen, and CH_2-COOH ;

X is selected from CH_2 and $C=O$;

or pharmaceutically acceptable salts and esters thereof and isomers thereof.

Preferably, the compound of formula II is selected from:

2-methyl-3-(3,5-diiodo-4-hydroxy-benzoyl)benzofuran (E5);

2-methyl-3-(3,5-diiodo-4-carboxymethoxy-benzyl)benzofuran (E6);

and pharmaceutically acceptable salts, esters, and isomers thereof.

Another embodiment of the present invention relates to pharmaceutical compositions for the treatment of atrial fibrillation or atrial flutter comprising at least one compound of formula I or II, if appropriate together with a pharmaceutically-acceptable carrier

Yet another embodiment of the present invention relates to a method of treating atrial fibrillation or atrial flutter comprising providing to a patient in need thereof a pharmaceutically effective amount of at least one compound of formula I or II.

The synthesis and detailed description of the compounds of formula II are described in WO 96/0510 and WO 92/20331.

The compounds of formula I and formula II can be used in combination with other agents useful for treating atrial fibrillation and atrial flutter. The individual components of such combinations can be administered separately at different times during the course of therapy or concurrently in divided or single combination forms. The instant invention is therefore to be understood as embracing all such regimes of simultaneous or alternating treatment and the term "administering" is to be interpreted accordingly. It will be understood that the scope of combinations of the compounds of this invention with other agents useful for treating atrial fibrillation and atrial flutter includes in principle any combination with any pharmaceutical composition useful for treating atrial fibrillation and atrial flutter.

The compounds of formulae I and II can be administered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powder, granules, elixirs, tinctures, suspensions, syrups and emulsions. Likewise, they may also be administered in intravenous (bolus or infusion), intraperitoneal, topical (*e.g.*, skin cream or ocular eyedrop), subcutaneous, intramuscular, or transdermal (*e.g.*, patch) form, all using forms well known to those of ordinary skill in the pharmaceutical arts.

The dosage regimen utilizing these compounds is selected in accordance with a variety of factors including type, species, age, weight, sex, and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed. An ordinarily skilled physician, veterinarian or clinician can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.

Oral dosages of the compounds, when used for the indicated effects, will range between about 0.01 mg per kg of body weight per day (mg/kg/day) to about 100 mg/kg/day, preferably 0.01 mg per kg of body weight per day (mg/kg/day) to 10 mg/kg/day, and most preferably 0.1 to 5.0 mg/kg/day. For oral administration, the compositions are preferably provided in the form of tablets containing 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. A medicament typically contains from about 0.01 mg to about 500 mg of the active ingredient, preferably from about 1 mg to about 100 mg of active ingredient. Intravenously, the most preferred doses will range from about 0.1 to about 10 mg/kg/minute during a constant rate infusion. Advantageously, compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily. Furthermore, preferred compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in the art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.

The specific compounds of formulae I and II described herein can form the active ingredient, and are typically administered in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as "carrier" materials) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices.

For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic,

pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms includes sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include without limitation starch, methylcellulose, agar, bentonite, xanthan gum and the like.

The compounds of formulae I and II can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as 1,2-dipalmitoylphosphatidylcholine, phosphatidyl ethanolamine (cephalin), or phosphatidylcholine (lecithin)

The following definitions apply to the terms as used throughout this specification, unless otherwise limited in specific instances.

The term "alkyl" as employed herein refers to those groups of the designated number of carbon atoms in either a straight and branched chain hydrocarbons, such as methyl, ethyl, propyl, iso-propyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, 2-methylpentyl, and the like.

The term "alkoxy" as employed herein refers to a straight or branched chain radical attached through an oxygen linkage, containing 1, 2, 3 or 4 carbon atoms in the normal chain. Examples of such alkoxy groups are methoxy, ethoxy, propoxy, butoxy, isobutoxy and the like.

The compounds of formulae I and II can be present as salts, in particular pharmaceutically acceptable salts. If they have, for example, at least one basic center, they can form acid addition salts. These are formed, for example, with strong inorganic acids, such as mineral acids, for example sulfuric acid, phosphoric acid or a hydrohalic acid, with strong organic carboxylic acids, such as alkanecarboxylic acids of 1 to 4 carbon atoms which are unsubstituted or substituted, for example, by halogen, for example acetic acid, such as saturated or unsaturated dicarboxylic acids, for example oxalic, malonic, succinic, maleic, fumaric, phthalic or terephthalic acid, such as hydroxycarboxylic acids, for example ascorbic, glycolic, lactic, malic, tartaric or citric acid, such as amino acids, (for example aspartic or glutamic acid or lysine or arginine), or benzoic acid, or with organic sulfonic acids, such as (C₁-C₄)-alkyl- or aryl-sulfonic acids which are unsubstituted or substituted, for example by halogen, for example methane- or p-toluene-sulfonic acid. Corresponding acid addition salts can also be formed having, if desired, an additionally present basic center. The compounds of formulae I and II having at least one acid group (for example COOH) can also form salts with bases. Suitable salts with bases are, for example, metal salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium or magnesium salts, or salts with ammonia or an organic amine, such as morpholine, thiomorpholine, piperidine, pyrrolidine, a mono-, di- or tri-lower alkylamine, for example ethyl-, tert-butyl-, diethyl-, diisopropyl-, triethyl-, tributyl- or dimethyl-propylamine, or a mono-, di- or trihydroxy lower alkylamine, for example mono-, di- or triethanolamine. Corresponding internal salts may furthermore be formed. Salts which are unsuitable for pharmaceutical uses but which can be employed, for example, for the isolation or purification of free compounds or their pharmaceutically acceptable salts are also included.

Preferred salts of the compounds of formulae I and II which include a basic group include monohydrochloride, hydrogensulfate, tartrate, fumarate or maleate. Preferred salts of the compounds which include an acid group include sodium, potassium and magnesium salts and pharmaceutically acceptable organic amines.

The compounds of formulae I and II may contain one or more chiral centers and therefore may exist as optical isomers. The invention therefore comprises the optically inactive racemic (*rac*) mixtures (a one to one mixture of enantiomers), optically enriched scalemic

mixtures as well as the optically pure individual enantiomers. The compounds in the invention also may contain more than one chiral center and therefore may exist as diastereomers. The invention therefore comprises individual diastereomers as well as mixtures of diastereomers in cases where the compound contains more than one stereo center. The compounds in the invention also may contain acyclic alkenes or oximes and therefore exist as either the E (entgegen) or Z (zusammen) isomers. The invention therefore comprises individual E or Z isomers as well as mixtures of E and Z isomers in cases where the compound contains an acyclic alkene or oxime functional group. Also included within the scope of the invention are polymorphs, hydrates, and solvates of the compounds of the instant invention.

The present invention includes within its scope prodrugs of the compounds of formulae I and II. In general, such prodrugs will be functional derivatives of the compounds of this invention which are readily convertible *in vivo* into the required compound. Thus, in the methods of treatment of the present invention, the term "administering" shall encompass the treatment of the various conditions described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound *in vivo* after administration to the patient. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example in "Design of Prodrugs" ed. H. Bundgaard, Elsevier, 1985, which is incorporated by reference herein in its entirety. Metabolites of the compounds includes active species produced upon introduction of compounds of this invention into the biological milieu.

The novel compounds of formula I can be prepared according to the following schemes and non-limiting examples, using appropriate materials and are further exemplified by the following non-limiting specific examples. The examples further illustrate details of the preparation of compounds of formula I. Those skilled in the art will readily understand that known variation of the conditions and processes of the following preparative procedures can be used to prepare these compounds.


The compounds of formula I are prepared according to the general methods outlined in **Schemes 1** and **2**, and according to the methods described. Examples of reagents and procedures for these reactions appear hereinafter and in the working examples.

Compounds of formula I of the invention where X is a carbonyl group (C=O), R₂ is hydrogen, and where variations can be introduced at the R₁, R₃, R₄ and R₅ positions can be prepared using the method outlined below and indicated in **Scheme 1** (Examples 1 and 2). In the method, benzofuran **1** is regioselective acylated at the β -position by an acyl chloride **2** in the presence of a Lewis catalyst such as tin tetrachloride, to give the coupled material **3** after standard work-up. A huge collection of different methods for the acylation of aromatics is available in the literature (see for example: Jerry March in *Advanced Organic Chemistry*, 4th ed, 1992, John Wiley & Sons, Inc, p 539-542 and references cited therein), several of which could be applied in the present method.

The methyl ether function can be removed by treatment of **3** with 1-2 equivalents of a Lewis acid such as boron tribromide at low temperature and in an inert solvent such as dichloromethane or benzene. The reaction mixture gives after standard work-up and purification, the end product **4**. Several alternative methods for demethylation of anisol derivatives are available in the literature, some which might be applied for the conversion of **3** to **4**. Examples of such alternative methods include the use of: (i) AlBr₃/ethanethiol, Node Manubu et al, *Tetrahedron Lett.*, 1989; (ii) BF₃/dimethyl sulfide, Bindal R. D., Katzenellenbogen J. A., *J. Org. Chem.*, 1987, pp 3181; (iii) HBr/acetic acid, Takeshita Hitosh, *Bull. Chem. Soc. Jpn.*, 1986, pp 1125; and the like.

The phenol **4** is finally O-alkylated employing the appropriate halide in the presence of a base such as potassium carbonate and then further treated with a base, to give the end product containing a carboxymethoxy function. Several alternative methods for the O-alkylation of phenols and hydrolysis of carboxylic acid esters have been published in the literature, several which might be applied for the conversion of **4** to **5**.


Scheme 1



4: Example 1: $R_1=\text{Me}$, $R_2=\text{H}$; $R_3=R_4=\text{i-Pr}$

5: Example 2: $R_1=\text{Me}$, $R_2=\text{H}$; $R_3=R_4=\text{i-Pr}$

Compounds of formula I of the invention where X is a methylene group ($-\text{CH}_2-$), R_2 is hydrogen and where variation can be introduced at the R_1 , R_3 , R_4 and R_5 positions can be prepared using the method outlined below and indicated in **Scheme 2** (Examples 3 and 4). In the method, the carbonyl group ($\text{C}=\text{O}$) of 3 is reduced to a methylene group ($-\text{CH}_2-$) employing a combination of lithium aluminium hydride and aluminium trichloride as reducing agent. Several other methods for the reduction of carbonyl groups to methylene groups are known in the literature and might be used here with successful results and are well known to those skilled in the art (see for example: Jerry March in *Advanced Organic Chemistry*, 4th ed, 1992, John Wiley & Sons, Inc, p 1209-1211 and references cited therein). The reaction mixture yields after standard work-up the corresponding reduced material 7, which can be further reacted further to give the carboxymethoxy 8 using the same method as described above.



Example 3: $R_1 = \text{Me}$, $R_3 = R_4 = i\text{-Pr}$

Example 4: $R_1 = \text{Me}$, $R_3 = R_4 = i\text{-Pr}$

EXAMPLES

The following Examples represent preferred compounds of formula I of the present invention. However, they should not be construed as limiting the invention in any way. The following abbreviations, reagents, expressions or equipment, which are amongst those used in the descriptions below, are explained as follows: gas chromatography mass spectroscopy (GC-MS), electron impact (EI); liquid chromatography mass spectroscopy (LC-MS), electrospray (ES), ethyl acetate (EtOAc).

Example 1: 2-methyl-3-(3,5-diisopropyl-4-hydroxybenzoyl)benzofuran (E1)

(a) A stirred mixture of 3,5-diisopropyl-4-methoxybenzoic acid (5 mmol, 1.2 g) and phosphorous pentachloride (1.3 g, 6.0 mmol) in dichloromethane (50 mL) was refluxed for two hours. The reaction mixture was cooled down to room temperature, 2-methylbenzofuran (0.76 g, 5 mmol) was added followed by tin tetrachloride (1.3 g, 5 mmol). After two hours the organic solvent was removed and the residue solved in EtOAc, washed with hydrochloric acid (2 N), sodium hydroxide (1 N) and finally with an aqueous saturated solution of sodium chloride. The organic phase was dried over magnesium sulphate. The crude product was purified on column (silica gel, petroleum ether/EtOAc 9:1) to give 1.7 g (97%) of 2-methyl-3-(3,5-diisopropyl-4-methoxybenzoyl)benzofuran as a colorless oil, which slowly solidified at room temperature: $^1\text{H NMR}$ (CD_3COCD_3) δ 1.22

(d, 12H, CHCH₃, J=6.9), 2.50 (s, 3H, CH₃), 3.82 (s, 3H, OCH₃), 7.24-7.56 (m, 4H, aromatics), 7.65 (s, 2H, H-2' and H-6'); MS (ES) m/z 351 (M-1).

(b) A stirred solution of 2-methyl-3-(3,5-diisopropyl-4-methoxybenzoyl)benzofuran (1.7 g, 4.8 mmol) in 20 mL of dichloromethane was kept under nitrogen and cooled to -40°C. To the solution was added boron tribromide (6.0 mL, 1 N, solution in dichloromethane) and left at room temperature over night. The reaction mixture was treated with cold hydrochloric acid (1 N), the phases were separated and the organic phase was washed once with water. The organic phase was dried over magnesium sulphate, filtrated and concentrated. The residue was subjected to column (silica gel, petroleum ether/EtOAc 8:1) to give 2-methyl-3-(3,5-diisopropyl-4-hydroxybenzoyl)benzofuran as a pale yellow crystal mass (1.3 g, 81%): ¹H NMR (Acetone-d₆) δ 1.21 (d, 12H, CHCH₃, J=6.9), 2.51 (s, 3H, CH₃), 3.41 (m, 1H, CH), 7.57-7.21 (m, 4H, aromatics), 7.64 (s, 2H, H-2' and H-6'); GC-MS (EI, 70 eV) m/z 336 (M⁺).

Example 2: 2-Methyl-3-(3,5-diisopropyl-4-carboxymethoxybenzoyl)benzofuran (E2)

A mixture of 2-methyl-3-(3,5-diisopropyl-4-hydroxybenzoyl)benzofuran (170 mg, 0.5 mmol) and K₂CO₃ (138 mg, 1 mmol) in dry acetone (10 mL), α-brom ethylacetate (170 mg, 1 mmol) was added during 5 minutes, the solution was stirred over night at room temperature. Ethyl acetate was added and the solution was washed with water. The organic phase was evaporated to dryness and the residue was dissolved in a mixture of methanol (2 mL) and sodium hydroxide (2 mL, 1 N). The solution was stirred at room temperature over night, extracted with ethyl acetate and dried over magnesium sulphate. Evaporation of the organic phase gave 1.1 g which was purified on column (silica gel, chloroform/methanol/acetic acid 95:5:1): ¹H NMR (CD₃COCD₃) δ 1.21 (d, 12H, CHCH₃, J=6.9), 2.50 (s, 3H, CH₃), 3.49 (m, 1H, CH), 4.56 (s, 2H, CH₂), 7.21-7.61 (m, 4H, aromatics), 7.66 (s, 2H, H-2' and H-6'); LC-MS (ES) m/z 393(M⁺-1).

Example 3: 2-Methyl-3-(3,5-diisopropyl-4-hydroxybenzyl)benzofuran (E3)

Aluminium trichloride (120 mg, 4 mmol) in diethyl ether (1.5 mL) was added to a suspension of lithiumaluminiumhydride (40 mg, 2 mmol) in diethyl ether (1 mL) during 20 minutes at 0°C. 2-Methyl-3-(3,5-diisopropyl-4-hydroxybenzoyl)benzofuran (330 mg, 1 mmol) in 3 mL of ether was added, and the mixture then stirred at room temperature for

two hours. Excess of the reagent was destroyed by adding water (1 mL) and sodium hydroxide (0.1 mL). Ethyl acetate (100 mL) was added, and the organic layer was washed with sodium bicarbonate and dried over magnesium sulphate. The organic phase was evaporated and the residue and purified on column (petroleum ether/EtOAc 9:1) to give 290 mg (90 %) of 2-methyl- 3-(3,5-diisopropyl-4- hydroxybenzyl)benzofuran as a red oil: GC-MS (EI, 70 eV) m/z (%) 322(M⁺).

Example 4: 2-Methyl-3-(3,5-diisopropyl-4-carboxymethoxybenzyl)benzofuran (E4)

This compound was prepared from

2-methyl-3-(3,5-diisopropyl-4-hydroxybenzyl)benzofuran (290 mg, 1 mmol) and a-brom ethylacetate (230 mg, 1.5 mmol), using the procedure described in Example 2. The crude product was purified on column (chloroform/methanol/ acetic acid 95:5:1) to give 300 mg (79 %) of 2-methyl-3-(3,5-diisopropyl-4-carboxymethoxy- benzyl)benzofuran as a white crystal mass: ¹H NMR (CD₃COCD₃) δ 1.15 (d, 12H, CHCH₃, J=6.9), 2.46 (s, 3H, CH₃), 3.34 (m, 1H, CH), 3.97 (s, 2H, CH₂), 4.37 (s, 2H, CH₂), 7.05-7.45 (m, 4H, aromatics), 7.10 (s, 2H, H-2' and H-6'); LC-MS (ES) m/z 379 (M⁺-1).

The following Table 1 illustrates the potency (IC₅₀-values) of compounds of formulae I and II compared with other anti-arrhythmic drugs to inhibit the transmembrane currents I_K(Ado) and I_K(ACh) after stimulation of the currents with Adenosine or Acetylcholine (or Carbachol).

Table 1: Potency (IC₅₀-values) of compounds of the invention and other anti-arrhythmic drugs to inhibit the transmembrane currents IK(Ado) and IK(ACh) after stimulation of the currents with Adenosine or Acetylcholine (or Carbachol).

IC₅₀: Molar concentration of a compound at which 50% inhibition of the induced activity occurs.

Compound	Inhibition of IK(Ado) Induced by Adenosine	Inhibition of IK (ACh) (Induced by ACh or Carbachol)
d,l-sotalol (Mori)	No effect	36 μ M (IC ₅₀)
Propranolol (Brandts)	8 μ M (IC ₅₀)	56 μ M (IC ₅₀)
E-4031 (Mori)	Some effect at 100 μ M	8 μ M (IC ₅₀)
MS-551 (Mori)	Some effect at 100 μ M	11 μ M (IC ₅₀)
Aprinidine (Ohmoto)	Not studied	0.4 μ M (IC ₅₀)
Amiodarone (Watanabe)	2 μ M (IC ₅₀)	2 μ M (IC ₅₀)
Terikalant (Brandts)	2 μ M (IC ₅₀)	2 μ M (IC ₅₀)
SUN 1165 (Inomata)	Not studied	29 μ M (IC ₅₀)
Flecainide (Inomata)	Not studied	3.6 μ M (IC ₅₀)
Disopyramide (Inomata)	Not studied	1.7 μ M (IC ₅₀)
Quinidine (Inomata)	Not studied	1.6 μ M (IC ₅₀)
Dronedarone (Guillemare)	Not studied	0.01 μ M (IC ₅₀)
E5	1 μ M (IC ₅₀)	1 μ M (IC ₅₀)
E6	Similar to E5 (100% Inh at 50 μ M)	Similar to E5 (100% Inh at 50 μ M)
E4	100% Inh at 50 μ M	100% Inh at 50 μ M

IC₅₀: Molar concentration of a compound at which 50% inhibition of the induced activity occurs.

E5 is 2-methyl-3-(3,5-diiodo-4-hydroxy-benzoyl)benzofuran. (Formula II)

E6 is 2-methyl-3-(3,5-diiodo-4-carboxymethoxy-benzyl)benzofuran. (Formula II)

E4 is 2-methyl-3-(3,5-diisopropyl-4-carboxymethoxybenzyl)benzofuran. (Formula I)

For references, see Table 2.

Table 2: Comparison of blocking activity of E4 and E6 and other antiarrhythmic drugs on different transmembrane ion-currents.

	IK(Ado)	IK(ACh)	IK(ATP)	IK1	IKs	Ito	INa
E4, E6	Yes	Yes	Yes	No	No	No	No
Quinidine	U	Yes (Inomata)	Yes (Undrovi)	No (Slawsky)	No (Lai)	Yes (Slawsky)	Yes (Slawsky)
Flecainide	U	Yes (Inomata)	Yes (Sato)	No (Slawsky)	No (Wang)	Yes (Slawsky)	Yes (Konzen)
Disopyramide	U	Yes (Inomata)	Yes (Wu)	No (Sato)	Yes (Sato)	Yes (Sato)	Yes (Sato)
Aprinidine	U	Yes (Ohmoto)	U	No (Ohmoto)	No (Ohmoto)	Yes (Tanaka)	Yes (Ohmoto)
Terikalant (RP58866)	Yes (Brandts)	Yes (Brandts)	No (Brandts)	Yes (Yang)	Yes (Yang)	Yes (Yang)	No (Yang)
d,l-Sotalol	No (Mori)	Yes (Mori)	U	Yes (Berger)	No (Lai)	Yes (Berger)	No (Malecot)
Amiodarone	Yes (Watanabe)	Yes (Watanabe)	Yes (Holmes)	Yes (Kodama)	Yes (Kodama)	U	Yes (Kodama)
Dronedarone	U	Yes (Guillemaire)	U	U	Yes (Guillemaire)	U	Yes (Guillemaire)

Explanations

- Yes:** The compound has been demonstrated to inhibit the particular current (reference within parenthesis).
- No:** The compound has been demonstrated to not inhibit the particular current (reference within parenthesis).
- U:** No data regarding interaction of the compound with the particular current has been found in the literature.

IK(Ado): Adenosine activated K-current

IK(ACh): AcetylCholine activated K-current

IK(ATP): ATP-sensitive K-current

IK1: Inward rectifier K-current

IKs: Slow component of the delayed rectifier K-current

Ito: Transient outward K-current


INa: Depolarizing Na-current

Table 2 References:

- Inomata N. et al. *Br J Pharmacol* 1991 Dec;104(4):1007-11.
- Guillemare E. et al. Marion A, Nisato D, Gautier P. *J Cardiovasc Pharmacol* 2000 Dec;36(6):802-5.
- Undrovinas AI. et al. *Am J Physiol* 1990 Nov;259(5 Pt 2):H1609-12.
- Slawsky MT,. And Castle NA. *J Pharmacol Exp Ther* 1994 Apr;269(1):66-74.
- Lai L. et al. *J Biomed Sci* 1999 Jul-Aug;6(4):251-9.
- Satoh H *Eur J Pharmacol* 2000 Oct 27;407(1-2):123-9 .
- Wang DW, et al. *Cardiovasc Res* 1995 Apr;29(4):520-5.
- Konzen G. et al. *Arch Pharmacol* 1990 Jun;341(6):565-76.
- Wu B. et al. *Cardiovasc Res* 1992 Nov;26(11):1095-101.
- Tanaka H. et al. *Naunyn Schmiedebergs Arch Pharmacol* 1990 Apr;341(4):347-56.
- Yang BF. et al. *Zhongguo Yao Li Xue Bao* 1999 Nov;20(11):961-9.
- Berger F. et al. *Arch Pharmacol* 1989 Dec;340(6):696-704.
- Holmes DS. Et al. *J Cardiovasc Electrophysiol* 2000 Oct;11(10):1152-8.
- Mori K. et al. *Circulation* 1995 Jun 1;91(11):2834-43 .
- Ohmoto-Sekine Y. et al. *Br J Pharmacol* 1999 Feb;126(3):751-61.
- Watanabe Y. et al. *J Pharmacol Exp Ther* 1996 Nov;279(2):617-24.
- Brandts B. et al. *Pacing Clin Electrophysiol* 2000 Nov;23(11 Pt 2):1812-5.

CLAIMS

1. A compound according to formula I;



wherein;

R₁ is C₁-C₄ alkyl;

R₂ is NHCOR^a, NHCONHR^a, or hydrogen;

R₃ and R₄ are independently selected from fluorine, chlorine, C₁-C₆ alkyl, and CF₃;

R^a is selected from CF₃, C₁₋₃ alkyl, and -(4-R^b)C₆H₄;

R^b is selected from C₁₋₄ alkoxy, hydroxy, fluoro, and nitro;

R₅ is selected from hydrogen and -CH₂-COOH;


X is selected from CH₂ and C=O; with the proviso that when R₅ is hydrogen, X is -CH₂-;

and pharmaceutically acceptable salts, esters and isomers thereof.

2. A compound according to claim 1 wherein R₂ is hydrogen or NHCOR^a and each of R₃ and R₄ is independently C₁-C₄ alkyl.
3. A compound according to claim 2 wherein R₃ and R₄ are isopropyl.
4. A compound according to claim 1 where R₂ is H or NHCOR^a, or claim 2 or 3, wherein R₅ is -CH₂-COOH.
5. A compound according to claim 1 wherein R₁ is methyl; R₂ is hydrogen; R₃ and R₄ is C₁-C₄ alkyl; R₅ is -CH₂-COOH; and X is -CH₂-.

6. 2-methyl-3-(3,5-diisopropyl-4-hydroxybenzoyl)benzofuran (E1); or
2-methyl-3-(3,5-diisopropyl-4-carboxymethoxybenzoyl)benzofuran (E2); or
2-methyl-3-(3,5-diisopropyl-4-hydroxybenzyl)benzofuran (E3); or
2-methyl-3-(3,5-diisopropyl-4-carboxymethoxybenzyl)benzofuran (E4); or
and pharmaceutically acceptable salts, esters and isomers thereof.
7. A compound according to any one of claims 1 to 6 for use in medical therapy.
8. A pharmaceutical composition comprising a compound according to any one of claims 1 to 6, together with a pharmaceutically acceptable carrier.
9. A method of treating atrial fibrillation or atrial flutter comprising providing to a patient in need thereof a pharmaceutically effective amount of a compound according to any one of claims 1 to 6.
10. The use of a compound according to any one of claims 1 to 6 in the preparation of a medicament for the treatment or prevention of atrial fibrillation or atrial flutter.
11. Pharmaceutical use of a compound that inhibits transmembrane potassium currents that are more active in the diseased atrium of a mammalian heart than in a normal atrium, without affecting other ion channels, for the preparation of a medicament for the treatment or prevention of atrial fibrillation and atrial flutter.
12. The use according to claim 11, wherein the said inhibition derives from inhibition of one or more of the three ligand-gated potassium currents IK(Ado), IK(ACh) and IK(ATP).
13. The use according to claim 11 or 12, wherein the said inhibition caused by the compound is not due to a T3 antagonistic effect.

14. The use according to any one of claims 11 to 13, wherein the compound is a compound according to formula II:



II

wherein;

R⁶ is C1-C4 alkyl;

R⁷ is NHCOR⁵, NHCONHR⁵, or hydrogen;

R⁸ and R⁹ are independently selected from iodine and bromine;

R¹⁰ is selected from CF₃, C1-3 alkyl, and 4-R₆C₆H₄;

R¹¹ is selected from C1-4 alkoxy, hydroxy, fluoro, and nitro;

R¹² is selected from hydrogen, and CH₂-COOH;

X is selected from CH₂ and C=O;

or pharmaceutically acceptable salts, esters and isomers thereof.

15. The use according to any one of claims 11 to 14, wherein the compound is
 2-methyl-3-(3,5-diiodo-4-hydroxy-benzoyl)benzofuran (**E5**);
 2-methyl-3-(3,5-diiodo-4-carboxymethoxy-benzyl)benzofuran (**E6**);
 or pharmaceutically acceptable salts and esters thereof and isomers thereof.
16. A pharmaceutical composition for the treatment of atrial fibrillation or atrial flutter comprising at least one compound that inhibits certain transmembrane potassium currents, which are more active in the diseased atrium of a mammalian heart than in a normal atrium, without affecting other ion channels.

17. The composition according to claim 16, wherein the said inhibition derives from inhibition of one or several of the three ligand-gated potassium currents IK(Ado), IK(ACh) and IK(ATP).
18. The pharmaceutical composition according to either claims 16 or 17, wherein the said inhibition caused by the compound is not due to a T3 antagonistic effect.
19. The pharmaceutical composition according to any one of claims 16 to 18, wherein the compound is a compound according to formula II as defined in claim 14.
20. The pharmaceutical composition according to claim 19, wherein the compound is 2-methyl-3-(3,5-diiodo-4-hydroxy-benzoyl)benzofuran (E5);
2-methyl-3-(3,5-diiodo-4-carboxymethoxy-benzyl)benzofuran (E6);
or pharmaceutically acceptable salts and esters thereof and isomers thereof.
21. A method of treating atrial fibrillation or atrial flutter comprising providing to a patient in need thereof a pharmaceutically effective amount of at least one compound that inhibits certain transmembrane potassium currents, that are more active in the diseased atrium of a mammalian heart than in a normal atrium, without affecting other ion channels.
22. The method according to claim 21, wherein the said inhibition derives from inhibition of one or several of the three ligand-gated potassium currents IK(Ado), IK(ACh) and (ATP).
23. The method according to either of claims 21 or 22, wherein the said inhibition caused by the compound is not due to a T3 antagonistic effect.
24. The method according to anyone of claims 21 to 23, wherein the compound is a compound according to formula II as defined in claim 14

25. The method according to anyone of claims 21 to 24, wherein the compound is
2-methyl-3-(3,5-diiodo-4-hydroxy-benzoyl)benzofuran (**E5**);
2-methyl-3-(3,5-diiodo-4-carboxymethoxy-benzyl)benzofuran (**E6**);
or pharmaceutically acceptable salts and esters thereof and isomers thereof.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/07905

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/343 A61P9/06 C07D307/80

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 58519 A (AMERICAN HOME PROD) 18 November 1999 (1999-11-18) Abstract; claims 1-2; examples 1,6,16.	1-10,14, 15,19, 20,24,25
A	EP 0 448 850 A (TARO PHARMA IND; TARO VIT IND LTD (IL)) 2 October 1991 (1991-10-02) Abstract; claims 1-8.	1-10,14, 15,19, 20,24,25
Y	WO 92 20331 A (KAROBIO AB) 26 November 1992 (1992-11-26) cited in the application	14,15, 19,20, 24,25
A	Page 1, line 35 to page 2, line 3; page 2, lines 20-24 and 30-33; page 3, lines 4-5.	1-10
	----- -/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

26 September 2002

Date of mailing of the international search report

07/10/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Weisbrod, T

PCT/EP 02/07905

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1,6,14,15,20,25 (all part); 11-13,16-18,21-23 (all complete)

Present claims 1, 6, 14, 15, 20, and 25 relate to compounds (I) and (II), respectively, as well as isomers thereof i.e. compounds having the same atomic composition. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, only for compounds of the formulae (I) and (II). Consequently, the search has been limited to the formulae (I) and (II) and the claims have not been searched in as far as isomers of the compounds (I) and (II) are concerned. In addition the substituents of formula (II) in claim 14 are not correctly assigned (cf. R5, R10). Therefore, claim 14 and claims referring to claim 14 have been searched based on the definition of formula (II) in the description (cf. page 11).

Furthermore, present claims 11-13, 16-18, and 21-23 relate to subject-matter defined by reference to a desirable characteristic or property of compounds "that inhibit transmembrane potassium currents that are more active in the diseased atrium of a mammalian heart than in a normal atrium, without affecting other ion channels". The claims cover all pharmaceutical uses, pharmaceutical compositions and therapeutic methods involving compounds of this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of compounds of the desired property. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the subject-matter by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to compounds of the formula (II) according to page 11 of the description (i.e. the claims 14-15, 19-20, and 24-25).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 02/07905

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 9 and 24-25 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound(s).
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 02/07905

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9958519	A	18-11-1999	AU 3791799 A	29-11-1999
			CA 2331120 A1	18-11-1999
			CN 1308621 T	15-08-2001
			EP 1077965 A1	28-02-2001
			JP 2002514636 T	21-05-2002
			WO 9958519 A1	18-11-1999
EP 0448850	A	02-10-1991	US 4975458 A	04-12-1990
			AU 617277 B2	21-11-1991
			AU 5217790 A	20-09-1990
			DK 448850 T3	15-01-1996
			EP 0448850 A1	02-10-1991
			GR 3017350 T3	31-12-1995
			ZA 9002271 A	28-08-1991
WO 9220331	A	26-11-1992	AT 141504 T	15-09-1996
			AU 660681 B2	06-07-1995
			AU 1774392 A	30-12-1992
			DE 69213003 D1	26-09-1996
			DE 69213003 T2	06-02-1997
			DK 584186 T3	09-09-1996
			EP 0584186 A1	02-03-1994
			ES 2090642 T3	16-10-1996
			GR 3021744 T3	28-02-1997
			JP 6507619 T	01-09-1994
			KR 235778 B1	15-12-1999
			WO 9220331 A1	26-11-1992
			US 5567728 A	22-10-1996
			US 5585404 A	17-12-1996
WO 9605190	A	22-02-1996	AT 172460 T	15-11-1998
			AU 694551 B2	23-07-1998
			AU 3345595 A	07-03-1996
			CA 2197185 A1	22-02-1996
			DE 69505542 D1	26-11-1998
			DE 69505542 T2	02-06-1999
			DK 775129 T3	28-06-1999
			WO 9605190 A1	22-02-1996
			EP 0775129 A1	28-05-1997
			ES 2123287 T3	01-01-1999
			JP 10504297 T	28-04-1998
			US 5854282 A	29-12-1998
US 4797415	A	10-01-1989	JP 1743663 C	15-03-1993
			JP 4033793 B	04-06-1992
			JP 59073579 A	25-04-1984
			DE 3332162 A1	19-04-1984
			FR 2534582 A1	20-04-1984
			GB 2131795 A , B	27-06-1984
			US 5004750 A	02-04-1991
			US 5175184 A	29-12-1992
			US 5274000 A	28-12-1993